CA
NZ
UK
AU
IND
US
The screener splits healthcare into health technology, which typically covers drug makers, biotechs and devices, and health services, which typically covers insurers and care providers. Health technology is last of 20 sectors on median one-week return, and Consumer Durables is next at negative 1.31%, …
Arbutus Biopharma (NASDAQ:ABUS) develops hepatitis B treatments and licenses lipid nanoparticle patents to Genevant, a company in which it owns about 16%. On March 3, 2026 Arbutus and Genevant settledPatentlitigation with Moderna. Moderna agreed to pay USD 950 million upfront, paid in July 2026, …
Myriad was downgraded to Underweight from Overweight at Piper Sandler with a USD 2 target in early September 2026, and UBS assumed coverage with a Neutral rating and a USD 3.60 target around September 9. Stephens had earlier cut its target to USD 3 …
The screener showsReturn on Equityof 29.49%, gross margin of 70.11%, anOperating Marginof negative 0.40% and net margin of 24.23%. The net margin ties to published trailing figures, with net income of USD 111.01 million on revenue of USD 458.09 million, up 34.4%. The July …
The screener tagged news, but no filing or release dated October 7 or 8, 2026 was found. The stock gapped up 8.88%, then traded 2.12% below its open, andVolumeof 7.1 million shares against about 3.06 million shares outstanding points to heavy short-term trading. The …
The screener flagged analyst action, but the nearest items found were a Barclays Sell initiation with a USD 8 target on October 6 and a Wells Fargo Hold with a USD 15 target on October 2, both from an aggregator and neither dated October …
The screener showed no catalyst, and none was found for October 7 or 8, 2026. The stock gapped up 0.59% and then climbed 5.00% from the open, which means buyers were active after the bell, thoughVolumewas only 159,143 shares, or 0.2 times normal. The …
On October 8, 2026 the company said the Japan Patent Office issued a notice of allowance for a method covering its CyPath Lung test, which uses automated flow cytometry andMachine Learningto detect early-stage lung cancer in sputum. Issuance follows payment of a fee. A …
Quanterix makes Simoa, an ultrasensitive technology that detects very low levels of proteins in blood and tissue. On September 14, 2026 it hired Dr. Yuri Fesko as chief medical officer to help launch the Lucent AD Complete five-biomarker Alzheimer's test and file the HD-X …
ImmunityBio closed at USD 7.72 on September 10, 2026, then climbed to USD 9.29 on September 22 on 21.1 million shares and USD 9.44 on September 30 on 27.3 million. On October 2 it rose 10.9% to USD 10.29 on 31.3 million shares, a …
Please wait processing your request...